Inside Precision Medicine June 10, 2024
The company utilizes approved drugs and clinically validated product candidates, along with big data and proprietary machine learning algorithms, to repurpose therapeutics for new indications
Clinical trials are where most drugs go to die, but they don’t need to stay gathering dust on the shelves for an eternity or ultimately disintegrate.
Derisking is always important in drug development, especially when dealing with the central nervous system (CNS), which has experienced lower success rates historically and, because of its complexity, takes longer to develop than other drug classes. A review from the National Institute of Aging (NIA) reported that the success rate of neuropsychiatric drug candidates entering human testing and consequently being approved is dramatically lower (8.2%) than for all drugs...
Today's Sponsors
Today's Sponsor